Lotus Pharmaceutical, a Taiwan-based company, has entered into an agreement with OM Pharma to acquire the assets of a specialty biopharmaceutical product for the prevention of recurrent urinary tract infections in South Korea.

• Asset Transfer: Includes marketing authorisations, trademarks, finished product inventory, and related intellectual property rights.
• Market Presence: The product is currently marketed in more than 40 countries and was used by over one million patients globally in 2025.
• Objective: The acquisition is intended to expand Lotus Pharmaceutical’s specialty portfolio and presence in the South Korean market.

This summary is based on a news article issued by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.